

Supplementary Table 4. Clinical outcomes among NAFLD participants by region

	European region			North America			Western Pacific + Southeast Asia			P-value
	Studies	Events/N	Incidence rate per 1,000 person-years	Studies	Events/N	Incidence rate per 1,000 person-years	Studies	Events/N	Incidence rate per 1,000 person-years	
Mortality										
All-cause mortality	14	9,660/ 140,785	19.34 (13.01–25.67)	9	64,337/ 271,898	14.99 (8.86–21.12)	10	1,076/ 98,423	7.54 (3.49–11.60)	0.0026
CVD-related mortality	8	1,378/ 12,685	7.01 (4.19–9.98)	4	576/ 5,366	5.22 (1.65–8.78)	7	198/ 97,419	1.30 (0.54–2.05)	<0.0001
Non-liver cancer mortality	6	1,439/ 12,209	4.79 (2.53–7.06)	5	555/ 5,651	2.80 (2.49–3.10)	8	423/ 97,903	1.65 (0.82–2.49)	<0.0001
Liver-related mortality	7	667/ 12,287	2.13 (1.53–2.72)	5	73/ 5,651	2.47 (0.00–4.98)	10	100/ 98,423	2.80 (0.68–4.93)	0.82
Non-liver cancer	2	1,555/ 9,363	12.55 (11.93–13.18)	1	628/ 4,722	16.62 (15.32–17.93)	7	952/ 14,700	7.49 (6.87–8.11)	<0.0001
Liver-related events										
Any liver event	12	5,070/ 273,854	28.58 (6.35–50.80)	10	102,838/ 290,669	32.12 (4.19–60.06)	14	294/ 36,435	12.41 (3.01–21.81)	0.22
Fibrosis progression	1	30/ 118	50.85 (32.65–69.04)	2	173/ 587	50.66 (0.00–104.73)	2	50/ 393	51.33 (0.00–118.10)	0.99
Cirrhosis	7	3,988/ 264,519	10.86 (5.52–16.19)	5	712/ 24,232	5.10 (2.23–7.97)	5	452/ 19,286	9.46 (0.00–20.23)	0.15
Liver transplant	2	6/ 222	1.85 (0.00–4.33)	4	66/ 1,600	25.36 (0.00–74.07)	1	11/ 284	9.11 (3.73–14.50)	0.038
HCC	8	703/ 273,220	2.39 (1.01–3.77)	6	104/ 25,280	0.37 (0.30–0.46)	12	164/ 36,042	4.08 (1.83–6.34)	0.0001
Cirrhotic decompensation										
Any decompensation	5	2,783/ 127,052	10.13 (4.28–15.99)	3	68/ 1,422	5.32 (0.16–10.48)	4	67/ 1,206	11.35 (0.00–25.15)	0.42
Ascites	3	35/ 766	6.40 (0.00–12.81)	3	28/ 1,422	2.25 (0.58–3.93)	3	31/ 932	7.31 (0.00–19.13)	0.35
Varices	2	6/ 622	1.95 (0.30–3.59)	2	31/ 1120	3.51 (0.00–7.48)	3	23/ 932	4.31 (0.57–8.06)	0.45
Encephalopathy	1	5/ 471	3.66 (0.45–6.87)	2	13/ 1120	1.56 (0.68–2.43)	3	19/ 932	3.85 (0.00–9.16)	0.34

Supplementary Table 4. Continued

	European region			North America			Western Pacific + Southeast Asia			P-value
	Studies	Events/N	Incidence rate per 1,000 person-years	Studies	Events/N	Incidence rate per 1,000 person-years	Studies	Events/N	Incidence rate per 1,000 person-years	
Metabolic outcomes										
HTN	6	111/ 965	12.98 (4.13–21.84)	1	94/ 420	43.04 (34.34–51.74)	5	717/ 4,206	36.57 (17.31–55.84)	<0.0001
HLD/DLD	2	46/ 329	22.00 (0.00–60.45)	3	581/ 8,158	21.16 (0.00–47.63)	2	258/ 1,062	39.08 (23.59–54.56)	0.43
DM	7	278/ 1,361	14.31 (10.34–18.27)	5	961/ 8,968	19.90 (6.63–33.17)	12	3786/ 29,160	22.88 (17.23–28.54)	0.048
Cardiovascular events										
Any CVD event	8	9,826/ 144,308	20.47 (9.52–31.43)	3	1,053/ 4,456	23.05 (6.43–39.67)	5	176/ 38,631	5.09 (1.25–8.94)	0.0059
CAD/CHF	3	2,871/ 22,524	37.58 (1.49–73.68)	3	683/ 4,456	11.48 (0.00–24.32)	N/A	N/A	N/A	0.18
MI	3	1,680/ 142,968	2.57 (1.76–3.38)	2	126/ 4,154	3.52 (1.10–5.94)	2	114/ 37,537	0.87 (0.00–2.30)	0.073
Stroke	5	3,320/ 143,444	4.45 (3.49–5.41)	2	230/ 4,154	6.45 (2.35–10.55)	N/A	N/A	N/A	0.35
Renal impairment	2	8,247/ 48,201	14.21 (7.98–20.45)	1	5,766/ 262,619	8.20 (7.99–8.41)	2	587/ 19,784	6.62 (2.80–10.44)	0.12

NAFLD, non-alcoholic fatty liver disease; CVD, cardiovascular disease; HCC, hepatocellular carcinoma; HTN, Hypertension; HLD, hyperlipidemia; DLD, dyslipidemia; DM, Diabetes mellitus; CAD, coronary artery disease; CHF, congestive heart failure; MI, myocardial infarction.